Atopic Dermatitis,Eczema (Atopic Dermatitis)
Atopic Dermatitis,Eczema (Atopic Dermatitis)

Clinical Trial for Atopic Dermatitis (7-8 Months)

Treatment: Injection Age: 18 Years

Seeking adults aged 18 to 65 years with a clinical diagnosis of atopic dermatitis (AD), with AD-involved body surface area (BSA) ≥ 10% at
(roughly the size of 10 palm prints or more).Inclusion criteria include having moderate to severe AD for at least 6 months prior and a history of
inadequate response to treatment for AD with topical medications.

Participants will receive either treatment via a subcutaneous injection (SC) or placebo Study treatment and study-related assessments will be
provided at no cost. Reimbursement for study-related expenses may be provided.

Study participation will last about 7-8 months and involve about 12 visits to the study centre.

Participating Locations

Participating Experts

Dr. Maryam Shayesteh Alam


Dr. Lorne Albrecht


Dr. Victoria Farley


Dr. Marnie Fisher


Dr. Wei Jing Loo


Dr. Elena Poulos


Dr. Mani Raman


Dr. Les A. Rosoph


Dr. Rocco Serrao


You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from

Last Update Posted: June 23, 2024

Official Title

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects With Moderate to Severe Atopic Dermatitis ID



AnaptysBio, Inc.

Study Description

  • Brief Summary:

    This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

  • Condition or Disease:

    Atopic Dermatitis Eczema

  • Intervention/Treatment:

    Drug: ANB032
    Drug: ANB032
    Drug: ANB032
    Drug: Placebo
  • Phase:

    Phase 2

  • Ages Eligible for Study:

    18 Years and 65 Years (Adult)

  • Sexes Eligible for Study:


Key Inclusion Criteria:

Male or female aged 18 to 65 years and in good general health
Moderate to severe AD for at least 6 months prior to Randomization
History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable
EASI score ≥ 16 at Screening and at Randomization
vIGA AD score ≥ 3 at Screening and at Randomization
AD involved BSA ≥ 10% at Screening and at Randomization

Key Exclusion Criteria:

Any factors that in the Investigator’s opinion would predispose the subject to develop an infection
Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject’s immune status
Not able to tolerate SC drug administration
Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization

Terms and Conditions –
Purpose of Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed to provide patients, family members, and members of the public current information about clinical research studies.


Learn More About

Atopic Dermatitis,Eczema (Atopic Dermatitis)

Learn More
2022 all rights reserved probity medical research inc
find a trial
filter trials
Skip to content